Company | Name | Exchange | Sector | Industry | Market Cap | P/E Ratio | PEG Ratio | Last Trade Price | Day Change (%) | Fair Value | Fair Value Upside | Fair Value Label | Analyst Price Target | Analyst Target Upside | Overall Health |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Vertex | NASDAQ | Healthcare | Biotechnology & Medical Research | $115.54B | -241.4x | 2.19 | $448.66 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 16.4% Upside | Upgrade to Pro+ | |
Regeneron Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $80.35B | 17.2x | 1.14 | $746.11 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Lonza Group AG | OTC Markets | Healthcare | Biotechnology & Medical Research | $42.28B | 67.6x | -1.34 | $58.50 | 0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.6% Upside | Upgrade to Pro+ | |
argenx ADR | NASDAQ | Healthcare | Biotechnology & Medical Research | $35.27B | -863.4x | -10.07 | $583.76 | 1.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 13.4% Upside | Upgrade to Pro+ | |
IQVIA Holdings | NYSE | Healthcare | Biotechnology & Medical Research | $35.02B | 24.9x | 0.89 | $192.96 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 35.9% Upside | Upgrade to Pro+ | |
BioNTech | NASDAQ | Healthcare | Biotechnology & Medical Research | $24.56B | -50.1x | 0.42 | $102.55 | -3.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.8% Upside | Upgrade to Pro+ | |
BeiGene ADS | NASDAQ | Healthcare | Biotechnology & Medical Research | $19.95B | -23.7x | -1.48 | $193.71 | 3.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
ICON PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $16.70B | 22.3x | 0.47 | $202.37 | 3.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 44.4% Upside | Upgrade to Pro+ | |
United Therapeutics | NASDAQ | Healthcare | Biotechnology & Medical Research | $16.30B | 15x | 0.58 | $365.47 | 1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 6.9% Upside | Upgrade to Pro+ | |
Summit Therapeutics PLC | NASDAQ | Healthcare | Biotechnology & Medical Research | $14.75B | -68.5x | -0.92 | $19.32 | -3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Moderna | NASDAQ | Healthcare | Biotechnology & Medical Research | $14.31B | -6.4x | -0.18 | $37.17 | -0.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Genmab AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $12.94B | 19.8x | 1.37 | $20.50 | -0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Insmed | NASDAQ | Healthcare | Biotechnology & Medical Research | $12.91B | -13x | 2.48 | $72.31 | -1.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 19.4% Upside | Upgrade to Pro+ | |
Neurocrine | NASDAQ | Healthcare | Biotechnology & Medical Research | $12.52B | 32x | 0.32 | $123.78 | 3.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 38.9% Upside | Upgrade to Pro+ | |
Bio-Techne | NASDAQ | Healthcare | Biotechnology & Medical Research | $10.85B | 71.3x | -1.9 | $68.43 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 28.1% Upside | Upgrade to Pro+ | |
Vaxcyte | NASDAQ | Healthcare | Biotechnology & Medical Research | $10.71B | -19.2x | 0.59 | $85.96 | -1.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Sarepta | NASDAQ | Healthcare | Biotechnology & Medical Research | $10.50B | 87.1x | 0.71 | $109.92 | 3.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Medpace Holdings | NASDAQ | Healthcare | Biotechnology & Medical Research | $10.08B | 27.4x | 0.78 | $325.80 | 3.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 10.5% Upside | Upgrade to Pro+ | |
Exelixis | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.85B | 21.8x | 0.05 | $34.46 | 0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | -2.6% Downside | Upgrade to Pro+ | |
EXACT Sciences | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.74B | -44.8x | -1.66 | $52.77 | -2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 29.8% Upside | Upgrade to Pro+ | |
Revolution Med | NASDAQ | Healthcare | Biotechnology & Medical Research | $9.53B | -16x | 2.2 | $56.71 | 0.4% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24% Upside | Upgrade to Pro+ | |
Charles River Laboratories | NYSE | Healthcare | Biotechnology & Medical Research | $9.50B | 23x | -1.75 | $185.68 | -0.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 18.2% Upside | Upgrade to Pro+ | |
Qiagen | NYSE | Healthcare | Biotechnology & Medical Research | $9.10B | 97.7x | -1.37 | $41 | 0.5% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 22.5% Upside | Upgrade to Pro+ | |
Tempus AI | NASDAQ | Healthcare | Biotechnology & Medical Research | $8.50B | -9.1x | 0.11 | $58.42 | 8.3% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 3.8% Upside | Upgrade to Pro+ | |
WuXi Biologics | OTC Markets | Healthcare | Biotechnology & Medical Research | $8.02B | -1.21 | $1.86 | 0% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | |||
Ascendis Pharma AS | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.44B | -16x | -0.71 | $125.17 | 0.6% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Legend Bio | NASDAQ | Healthcare | Biotechnology & Medical Research | $7.40B | -20.7x | -0.57 | $40.38 | 5.2% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | ||
Madrigal Pharma | NASDAQ | Healthcare | Biotechnology & Medical Research | $7B | -12.8x | 0.4 | $320.89 | 2.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 24.1% Upside | Upgrade to Pro+ | |
Nuvalent | NASDAQ | Healthcare | Biotechnology & Medical Research | $6.52B | -26.2x | 0.38 | $91.87 | 0.9% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 23.5% Upside | Upgrade to Pro+ | |
Blueprint Medicines Corp | NASDAQ | Healthcare | Biotechnology & Medical Research | $5.95B | -45.3x | -0.57 | $93.53 | -1.1% | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | Upgrade to Pro+ | 37.4% Upside | Upgrade to Pro+ |